AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26001905 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% sorghum diet and 40% rice diet (Experimental Group)
Number of subjects: 320
Study 26001905 — intervention group
Group type: COMPARATOR
Intervention: Regular rice diet (100%; Control Group)
Number of subjects: 320
Study 24927118 — intervention group
Group type: EXPERIMENTAL
Intervention: SevoBIS (n=31)
Number of subjects: 60
Study 24927118 — intervention group
Group type: COMPARATOR
Intervention: Sevo1.8% (n=29)
Number of subjects: 60
Study 22301204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp position
Number of subjects: 189
Study 22301204 — intervention group
Group type: COMPARATOR
Intervention: Sniff position
Number of subjects: 189
Study 20393347 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended buprenorphine/naloxone therapy (BUP) for 12 weeks
Number of subjects: 150
Study 20393347 — intervention group
Group type: COMPARATOR
Intervention: Detoxification for 2 weeks
Number of subjects: 150
Study 20393347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (BUP and detoxification)
Number of subjects: 150
Study 18350637 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole enteric-coated capsules (40 mg)
Number of subjects: 60
Study 18350637 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole magnesium (40 mg)
Number of subjects: 60
Study 16228116 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing Fatal Vision goggles
Number of subjects: 251
Study 16228116 — intervention group
Group type: COMPARATOR
Intervention: Watching those wearing the goggles
Number of subjects: 251
Study 16228116 — intervention group
Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 251
Study 16228116 — intervention group
Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 251
Study 12075272 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (6 1-g capsules providing 3 g eicosapentaenoic acid and 2.1 g docosahexaenoic acid/d)
Number of subjects: 339
Study 12075272 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 339
Study 10479129 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/didanosine (ddI)
Number of subjects: 55
Study 10479129 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine/ddI/nevirapine
Number of subjects: 55
Study 8141537 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (DuoDerm Extra Thin CGF)
Number of subjects: 28
Study 8141537 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing (Xeroform)
Number of subjects: 28
Study 3375323 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Group (n = 19) using trend-line approach
Number of subjects: 39
Study 3375323 — intervention group
Group type: COMPARATOR
Intervention: Visual Group (n = 20) using visual-inspection approach
Number of subjects: 39
Study 29603547 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 300
Study 29603547 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300
Study 29603547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CGM and standard treatment)
Number of subjects: 300
Study 28760648 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact chronic pain
Number of subjects: 1925
Study 28760648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest wealth quartile
Number of subjects: 1925
Study 28760648 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 1925
Study 28760648 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis and depression
Number of subjects: 1925
Study 24219890 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice chewed 15 times
Number of subjects: 15
Study 24219890 — intervention group
Group type: COMPARATOR
Intervention: Rice chewed 30 times
Number of subjects: 15
Study 22395583 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1600 IU cholecalciferol)
Number of subjects: 60
Study 22395583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19996335 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 minute walk test (6MWT)
Number of subjects: 123
Study 18446021 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of ascorbic acid and 400 IU of alpha-tocopherol for 6 months
Number of subjects: 66
Study 18446021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of ascorbic acid and 400 IU of alpha-tocopherol for 6 months
Number of subjects: 66
Study 18446021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 15872344 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT with attenuation correction
Number of subjects: 23
Study 15872344 — intervention group
Group type: COMPARATOR
Intervention: SPECT without attenuation correction
Number of subjects: 23
Study 15872344 — intervention group
Group type: COMPARATOR
Intervention: PET with (13)N-ammonia
Number of subjects: 23
Study 12881451 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg daily)
Number of subjects: 60
Study 12881451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10560218 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multisystemic therapy (MST)
Number of subjects: 116
Study 10560218 — intervention group
Group type: COMPARATOR
Intervention: Inpatient hospitalization
Number of subjects: 116
Study 8827790 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) levels in anemic newborns
Number of subjects: 30
Study 8827790 — intervention group
Group type: COMPARATOR
Intervention: Hb levels in IUTd and non-IUTd cases
Number of subjects: 30
Study 8827790 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo levels
Number of subjects: 30
Study 8827790 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticulocyte count
Number of subjects: 30
Study 8827790 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between Epo and Hb
Number of subjects: 30
Study 1593034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 514
Study 1593034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 6398983 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention group
Number of subjects: 201
Study 6398983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 201
Study 6398983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 6398983 — intervention group
Group type: COMPARATOR
Intervention: Monitored group
Number of subjects: 201
Study 30550982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-stimulation with anti-CD3
Number of subjects: 0
Study 30550982 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplements (16 weeks)
Number of subjects: 0
Study 30550982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-cellular flowcytometry analysis
Number of subjects: 0
Study 30104047 — intervention group
Group type: EXPERIMENTAL
Intervention: PPF-treated LLINs (permethrin plus pyriproxyfen)
Number of subjects: 4137
Study 30104047 — intervention group
Group type: COMPARATOR
Intervention: Standard LLINs (permethrin-only)
Number of subjects: 4137
Study 26312616 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of the Stroop task (mentally fatiguing treatment)
Number of subjects: 26
Study 26312616 — intervention group
Group type: COMPARATOR
Intervention: 30 min of reading magazines (control treatment)
Number of subjects: 26
Study 25382974 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Story Work Program (LSWp)
Number of subjects: 60
Study 25382974 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 60
Study 22261578 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (1.7 g of cis-9,trans-11 and trans-10,cis-12 CLA in 200 mL of sterilized milk twice daily for 12 weeks)
Number of subjects: 63
Study 22261578 — intervention group
Group type: COMPARATOR
Intervention: Placebo (salad oil in 200 mL of sterilized milk twice daily for 12 weeks)
Number of subjects: 63
Study 22261578 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation
Number of subjects: 63
Study 19703922 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner-quadrant tumors (n = 393)
Number of subjects: 1245
Study 19703922 — intervention group
Group type: COMPARATOR
Intervention: Outer-quadrant tumors (n = 852)
Number of subjects: 1245
Study 19703922 — intervention group
Group type: COMPARATOR
Intervention: Left-sided breast cancer
Number of subjects: 1245
Study 17484381 — intervention group
Group type: EXPERIMENTAL
Intervention: Test food (40 mg of soy isoflavone aglycone per day)
Number of subjects: 26
Study 17484381 — intervention group
Group type: COMPARATOR
Intervention: Placebo food
Number of subjects: 26
Study 16326296 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion blockade (SGB) performed on 19 patients before anesthesia induction
Number of subjects: 37
Study 16326296 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE) applied to determine contractile force
Number of subjects: 37
Study 16326296 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion blockade (SGB)
Number of subjects: 37
Study 16326296 — intervention group
Group type: COMPARATOR
Intervention: Control and blocked IMA segments
Number of subjects: 37
Study 11932472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (75 or 150 mg orally twice a day for 48 months)
Number of subjects: 41
Study 11932472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing tablets for 48 months)
Number of subjects: 41
Study 11932472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 41
Study 9751323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone in combination with steroids
Number of subjects: 0
Study 9751323 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine combinations with vinblastine, etoposide or paclitaxel
Number of subjects: 0
Study 9751323 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary hormonal therapies (alternative antiandrogens and anti‐adrenal agents)
Number of subjects: 0
Study 9751323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prostate specific antigen values with quality of life and measurable disease responses
Number of subjects: 0
Study 7790732 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment (50 mg suppository administered 30 min before hyperthermia)
Number of subjects: 5
Study 7790732 — intervention group
Group type: COMPARATOR
Intervention: No indomethacin pretreatment (control)
Number of subjects: 5
Study 1722918 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (Lomoparan, i.v. bolus injection of 3,250 anti‐Xa units followed by 750 units twice daily s.c. for 8 days)
Number of subjects: 8
Study 1722918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (500 mg orally 14 and 2 h before i.v. Org 10172 administration)
Number of subjects: 8
Study 1722918 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 and ASA combined
Number of subjects: 8
Study 1722918 — intervention group
Group type: COMPARATOR
Intervention: Org 10172 alone
Number of subjects: 8
Study 1722918 — intervention group
Group type: COMPARATOR
Intervention: ASA alone
Number of subjects: 8
Study 7152443 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-dose uricostatic and uricosuric regimen
Number of subjects: 0
Study 7152443 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30805830 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-delivered HIV risk reduction intervention (4 group sessions, 2 hours each)
Number of subjects: 14
Study 30805830 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-delivered HIV risk reduction intervention
Number of subjects: 14
Study 30805830 — intervention group
Group type: COMPARATOR
Intervention: Control (n=6)
Number of subjects: 14
Study 28700816 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Nocebo
Number of subjects: 446
Study 25915826 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of one portion of cake fortified with barley's beta‐glucan
Number of subjects: 23
Study 25915826 — intervention group
Group type: COMPARATOR
Intervention: Daily consumption of the same cake without the enrichment (placebo)
Number of subjects: 23
Study 24495660 — intervention group
Group type: EXPERIMENTAL
Intervention: Famous face
Number of subjects: 0
Study 24495660 — intervention group
Group type: EXPERIMENTAL
Intervention: Famous scene
Number of subjects: 0
Study 24495660 — intervention group
Group type: COMPARATOR
Intervention: Scrambled image
Number of subjects: 0
Study 24495660 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging (fMRI) for remember responses to words studied with famous faces
Number of subjects: 0
Study 24495660 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging (fMRI) for remember responses to words studied with famous scenes
Number of subjects: 0
Study 24495660 — intervention group
Group type: EXPERIMENTAL
Intervention: Know responses
Number of subjects: 0
Study 21406493 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 21
Study 21406493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20009964 — intervention group
Group type: EXPERIMENTAL
Intervention: aPV at birth and 1 month
Number of subjects: 76
Study 20009964 — intervention group
Group type: EXPERIMENTAL
Intervention: aPV at birth only
Number of subjects: 76
Study 20009964 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 17100971 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless pH monitoring
Number of subjects: 31
Study 17100971 — intervention group
Group type: COMPARATOR
Intervention: Catheter-based pH monitoring
Number of subjects: 31
Study 17100971 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for wireless pH monitoring
Number of subjects: 31
Study 15705733 — intervention group
Group type: EXPERIMENTAL
Intervention: World-class Spanish male endurance athletes
Number of subjects: 104
Study 15705733 — intervention group
Group type: COMPARATOR
Intervention: Spanish men (n = 164)
Number of subjects: 104
Study 11870807 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 11870807 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9854508 — intervention group
Group type: EXPERIMENTAL
Intervention: EET therapy (intravenous administration of IFN‐gamma or TNF‐SAM2 followed by OK‐432)
Number of subjects: 75
Study 9854508 — intervention group
Group type: EXPERIMENTAL
Intervention: EET therapy (more than 5 courses)
Number of subjects: 75
Study 9854508 — intervention group
Group type: EXPERIMENTAL
Intervention: EET therapy
Number of subjects: 75
Study 7874902 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal balloon protocol
Number of subjects: 23
Study 7874902 — intervention group
Group type: COMPARATOR
Intervention: Clinical protocol
Number of subjects: 23
Study 7874902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 23
Study 2212408 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled adenosine 5'-monophosphate (AMP)
Number of subjects: 8
Study 2212408 — intervention group
Group type: COMPARATOR
Intervention: Control (no AMP)
Number of subjects: 8
Study 329291 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms/kg N,N‐dimethyltryptamine (DMT) i.m.
Number of subjects: 38
Study 329291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31472930 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned delivery
Number of subjects: 901
Study 31472930 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (usual care)
Number of subjects: 901
Study 28659252 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotional SMS messages 3 times a week
Number of subjects: 353
Study 28659252 — intervention group
Group type: COMPARATOR
Intervention: Maternal and child health care messages (excluding breastfeeding-related messages) once a week
Number of subjects: 353
Study 28659252 — intervention group
Group type: EXPERIMENTAL
Intervention: Child morbidity and breastfeeding self-efficacy scores assessed at 1, 3, and 5 months postdelivery
Number of subjects: 353
Study 28659252 — intervention group
Group type: EXPERIMENTAL
Intervention: Social desirability measured at 5 months
Number of subjects: 353
Study 28659252 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages expressing delivery success and user experience assessed at the end of the study
Number of subjects: 353
Study 26349123 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulations (1450 ppm fluoride) with 2% isopentane
Number of subjects: 0
Study 26349123 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulations (1450 ppm fluoride) without 2% isopentane
Number of subjects: 0
Study 26349123 — intervention group
Group type: COMPARATOR
Intervention: Positive control dentifrice (1450 ppm fluoride)
Number of subjects: 0
Study 26349123 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice (0 ppm fluoride)
Number of subjects: 0
Study 26349123 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% isopentane dentifrice
Number of subjects: 0
Study 26349123 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% isopentane dentifrice
Number of subjects: 0
Study 23816493 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused integrated package of PMTCT services including task-shifting and point-of-care CD4 + cell count testing
Number of subjects: 0
Study 23816493 — intervention group
Group type: COMPARATOR
Intervention: Standard care (not explicitly mentioned but implied as control)
Number of subjects: 0
Study 22309473 — intervention group
Group type: COMPARATOR
Intervention: Neutral description of the child
Number of subjects: 124
Study 22309473 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious description of the child
Number of subjects: 124
Study 22309473 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio vignette intervention
Number of subjects: 124
Study 19883313 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide therapy
Number of subjects: 120
Study 19883313 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of T cell expansions (regardless of therapy)
Number of subjects: 120
Study 17565163 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 0
Study 17565163 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17565163 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with FFOV task
Number of subjects: 0
Study 15112860 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate (10 mg i.v.)
Number of subjects: 7
Study 15112860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11552902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridogrel (5 mg/day for 12 weeks)
Number of subjects: 85
Study 11552902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 9631813 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) delivering 100 microg of methacholine
Number of subjects: 40
Study 9631813 — intervention group
Group type: COMPARATOR
Intervention: Conventional nebulizer delivering methacholine
Number of subjects: 40
Study 7697689 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release cream
Number of subjects: 16
Study 7697689 — intervention group
Group type: COMPARATOR
Intervention: Standard cream
Number of subjects: 16
Study 3666661 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg orally)
Number of subjects: 6
Study 31922999 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.04 mg·kg)
Number of subjects: 406
Study 29433481 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy alone
Number of subjects: 121
Study 29433481 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy plus early ACLR
Number of subjects: 121
Study 29433481 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy plus delayed ACLR
Number of subjects: 121
Study 29433481 — intervention group
Group type: COMPARATOR
Intervention: Physical performance tests (hop, strength, balance)
Number of subjects: 121
Study 27126856 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone monotherapy
Number of subjects: 124
Study 25515553 — intervention group
Group type: EXPERIMENTAL
Intervention: Botanical oil (BO) combination (borage/echium oil)
Number of subjects: 59
Study 25515553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 59
Study 25515553 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (CO)
Number of subjects: 59
Study 22901969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (BIV) + 2-hour infusion after PCI
Number of subjects: 346
Study 22901969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (BIV)
Number of subjects: 346
Study 22901969 — intervention group
Group type: COMPARATOR
Intervention: Glycoprotein IIb/IIIa receptor inhibitor (GPI)
Number of subjects: 346
Study 19706207 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya protein isolate (SPI)
Number of subjects: 29
Study 19706207 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 29
Study 18761239 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block with 0.35 mL/kg of 0.5% levobupivacaine
Number of subjects: 12
Study 18761239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cervical plexus block with 0.2 mL/kg of 0.5% levobupivacaine (deep) and 0.15 mL/kg (superficial)
Number of subjects: 12
Study 15800312 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 126
Study 15800312 — intervention group
Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 126
Study 11821603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 200 mg dissolved in 100 ml saline
Number of subjects: 93
Study 11821603 — intervention group
Group type: COMPARATOR
Intervention: Saline 100 mg
Number of subjects: 93
Study 10765864 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 24): Irreversibly infected dentin was partially removed prior to the application of the bonding agent and restorative material.
Number of subjects: 48